Blood manganese and non-alcoholic fatty liver disease in a high manganese exposure area in China.
Case–control study
High manganese exposure area
Manganese
NAFLD
Journal
Journal of health, population, and nutrition
ISSN: 2072-1315
Titre abrégé: J Health Popul Nutr
Pays: Bangladesh
ID NLM: 100959228
Informations de publication
Date de publication:
06 Nov 2023
06 Nov 2023
Historique:
received:
05
09
2023
accepted:
29
10
2023
medline:
7
11
2023
pubmed:
6
11
2023
entrez:
5
11
2023
Statut:
epublish
Résumé
Manganese (Mn) deficiency and intoxication may affect nonalcoholic fatty liver disease (NAFLD) risk differently. We aimed to explore the association between blood Mn and NAFLD in an area with high Mn exposure in drinking water. We conducted a case-control study among 1407 patients with NAFLD and 1774 sex- and age-matched healthy controls in a physical examination population in Zhoushan hospital, Zhejiang province in China. We used the restricted cubic splines method to investigate the dose-response relationship. Logistic regression models were applied to determine the risk of NAFLD, and severity of NAFLD. The blood Mn concentration was higher in the NAFLD group than in the control group in women (16.1 ± 6.2 μg/L vs. 14.7 ± 6.4 μg/L, P = 0.022) and men (14.5 ± 6.3 μg/L vs. 13.6 ± 6.8 μg/L, P < 0.001). We found an inverted L shape relationship between blood Mn and NAFLD in both women and men. Compared to the lowest quartile, the adjusted odds ratio (OR) and 95% confidence interval (CI) of NAFLD for the highest quartile group was 1.646(1.222,2.217), 1.494(1.082,2.061), and 3.146(1.285,7.701) for the total population, men, and women. The positive relationship was only observed in those with fibrosis-4 score < 1.30 and normal alanine transaminase. Stratified analysis showed an interaction between smoking (P = 0.073), alcohol drinking (P = 0.013), and Mn, with a more prominent effect on the NAFLD in the never-smokers (OR = 2.153, 95% CI 1.408-3.290) and drinkers (OR = 2.596, 95% CI 1.608-4.191). Higher blood Mn is associated with an elevated NAFLD risk in the high Mn exposure areas, especially in nonsmokers and drinkers. Further studies are needed to verify this result in the areas with high Mn exposure.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Manganese (Mn) deficiency and intoxication may affect nonalcoholic fatty liver disease (NAFLD) risk differently. We aimed to explore the association between blood Mn and NAFLD in an area with high Mn exposure in drinking water.
METHODS
METHODS
We conducted a case-control study among 1407 patients with NAFLD and 1774 sex- and age-matched healthy controls in a physical examination population in Zhoushan hospital, Zhejiang province in China. We used the restricted cubic splines method to investigate the dose-response relationship. Logistic regression models were applied to determine the risk of NAFLD, and severity of NAFLD.
RESULTS
RESULTS
The blood Mn concentration was higher in the NAFLD group than in the control group in women (16.1 ± 6.2 μg/L vs. 14.7 ± 6.4 μg/L, P = 0.022) and men (14.5 ± 6.3 μg/L vs. 13.6 ± 6.8 μg/L, P < 0.001). We found an inverted L shape relationship between blood Mn and NAFLD in both women and men. Compared to the lowest quartile, the adjusted odds ratio (OR) and 95% confidence interval (CI) of NAFLD for the highest quartile group was 1.646(1.222,2.217), 1.494(1.082,2.061), and 3.146(1.285,7.701) for the total population, men, and women. The positive relationship was only observed in those with fibrosis-4 score < 1.30 and normal alanine transaminase. Stratified analysis showed an interaction between smoking (P = 0.073), alcohol drinking (P = 0.013), and Mn, with a more prominent effect on the NAFLD in the never-smokers (OR = 2.153, 95% CI 1.408-3.290) and drinkers (OR = 2.596, 95% CI 1.608-4.191).
CONCLUSION
CONCLUSIONS
Higher blood Mn is associated with an elevated NAFLD risk in the high Mn exposure areas, especially in nonsmokers and drinkers. Further studies are needed to verify this result in the areas with high Mn exposure.
Identifiants
pubmed: 37926847
doi: 10.1186/s41043-023-00467-2
pii: 10.1186/s41043-023-00467-2
pmc: PMC10626744
doi:
Substances chimiques
Manganese
42Z2K6ZL8P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
118Subventions
Organisme : Zhoushan Science and Technology Project
ID : 2018C11042
Organisme : CAMS Innovation Fund for Medical Sciences (CIFMS)
ID : 2016-I2M-3-001
Informations de copyright
© 2023. The Author(s).
Références
Chemosphere. 2022 Jan;287(Pt 4):132316
pubmed: 34592210
J Hepatol. 2018 Feb;68(2):305-315
pubmed: 29154965
Zhonghua Liu Xing Bing Xue Za Zhi. 2014 Aug;35(8):961-4
pubmed: 25376692
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Clin Nutr. 2021 Apr;40(4):2045-2052
pubmed: 33039155
Diabetes Res Clin Pract. 2011 Mar;91(3):333-41
pubmed: 21211861
J Hepatol. 2015 Apr;62(1 Suppl):S47-64
pubmed: 25920090
Int J Environ Res Public Health. 2019 Feb 11;16(3):
pubmed: 30754720
Arch Toxicol. 2021 Dec;95(12):3665-3679
pubmed: 34590183
Sci Rep. 2022 Mar 3;12(1):3550
pubmed: 35241770
Am J Physiol Heart Circ Physiol. 2011 Jan;300(1):H388-96
pubmed: 21057039
Biol Trace Elem Res. 2008 Apr;122(1):1-18
pubmed: 18193174
Oxid Med Cell Longev. 2018 Apr 5;2018:7580707
pubmed: 29849912
Environ Sci Pollut Res Int. 2023 Feb;30(9):22222-22231
pubmed: 36280639
Hepatology. 2010 May;51(5):1567-76
pubmed: 20432253
Gastroenterology. 2021 Feb;160(3):912-918
pubmed: 33307021
Sci Total Environ. 2020 Jun 10;720:137655
pubmed: 32146412
Curr Neurol Neurosci Rep. 2019 May 14;19(6):33
pubmed: 31089831
Clin Gastroenterol Hepatol. 2021 Apr;19(4):788-796.e4
pubmed: 32407969
Am J Gastroenterol. 2019 Mar;114(3):453-463
pubmed: 30353055
J Hepatol. 2017 Nov 02;:
pubmed: 29150142
J Epidemiol. 2013;23(2):115-21
pubmed: 23399520
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Liver Int. 2018 Aug;38(8):1487-1494
pubmed: 29359396
Circulation. 2018 May 29;137(22):2344-2356
pubmed: 29449338
Environ Health. 2013 Apr 15;12:30
pubmed: 23587294
Environ Res. 2022 Mar;204(Pt A):111923
pubmed: 34428452
Am J Lifestyle Med. 2017 Aug 23;13(6):602-605
pubmed: 31662726
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Endocr Metab Immune Disord Drug Targets. 2020;20(6):869-877
pubmed: 32065107
Hepatology. 2010 Jul;52(1):391; author reply 391-2
pubmed: 20578155
Environ Health Perspect. 2016 Dec;124(12):1876-1881
pubmed: 27258818
J Trace Elem Med Biol. 2021 Sep;67:126772
pubmed: 34000573
Eur Rev Med Pharmacol Sci. 2013 Jul;17(14):1916-22
pubmed: 23877857
Chemosphere. 2023 Oct;339:139598
pubmed: 37480945
Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108365
pubmed: 34083039